Search Immortality Topics:

Page 11234..1020..»

Category Archives: Pharmacogenomics

CYP2C9 – Wikipedia

Cytochrome P450 2C9 (abbreviated CYP2C9) is an enzyme that in humans is encoded by the CYP2C9 gene.[5][6] CYP2C9 is an important cytochrome P450 enzyme with a major role in the oxidation of both xenobiotic and endogenous compounds. CYP2C9 makes up about 18% of the cytochrome P450 protein in liver microsomes (data only for antifungal). Some 100 therapeutic drugs are metabolized by CYP2C9, including drugs with a narrow therapeutic index such as warfarin and phenytoin and other routinely prescribed drugs such as acenocoumarol, tolbutamide, losartan, glipizide, and some nonsteroidal anti-inflammatory drugs. Continue reading

Posted in Pharmacogenomics | Comments Off on CYP2C9 – Wikipedia

Irinotecan – Wikipedia

IrinotecanClinical dataTrade namesCamptosar (US), Campto (EU), Onivyde (liposomal)AHFS/Drugs.comMonographMedlinePlusa608043Pregnancycategory O=C7OCC=6C(=O)N2C(c1nc5c(c(c1C2)CC)cc(OC(=O)N4CCC(N3CCCCC3)CC4)cc5)=C/C=6[[email protected]@]7(O)CC Irinotecan, sold under the brand name Camptosar among others, is a medication used to treat colon cancer and small cell lung cancer.[1] For colon cancer it is used either alone or with fluorouracil.[1] For small cell lung cancer it is used with cisplatin.[1] It is given by slow injection into a vein.[1] Common side effects include diarrhea, vomiting, bone marrow suppression, hair loss, shortness of breath, and fever.[1] Other severe side effects include blood clots, colon inflammation, and allergic reactions.[1] Those with two copies of the UGT1A1*28 gene variant are at higher risk for side effects.[1] Use during pregnancy can result in harm to the baby.[1] Irinotecan is in topoisomerase inhibitor family of medication.[2] It works by blocking topoisomerase 1 which results in DNA damage and cell death.[1] Irinotecan was approved for medical use in the United States in 1996.[1] It is on the World Health Organization’s List of Essential Medicines, the most effective and safe medicines needed in a health system.[3] In the United Kingdom it is available as a generic medication and costs the NHS about 114.00 pounds per 100mg.[2] It is made from the natural compound camptothecin.[1] Its main use is in colon cancer, in particular, in combination with other chemotherapy agents. This includes the regimen FOLFIRI, which consists of infusional 5-fluorouracil, leucovorin, and irinotecan. The regimen XELIRI consists of capecitabine and irinotecan.[4][5] The most significant adverse effects of irinotecan are severe diarrhea and extreme suppression of the immune system.[6] Irinotecan-associated diarrhea is severe and clinically significant, sometimes leading to severe dehydration requiring hospitalization or intensive care unit admission Continue reading

Posted in Pharmacogenomics | Comments Off on Irinotecan – Wikipedia

UW-Madison study links nicotine addiction to genetic variation in … – Madison.com

Some smokers have more of an urge to light up right after they wake up, and UW-Madison researchers have identified a reason: genetic variation in a substance that breaks down nicotine in the brain. The finding, by scientists at UW-Madison and Washington University in St Continue reading

Posted in Pharmacogenomics | Comments Off on UW-Madison study links nicotine addiction to genetic variation in … – Madison.com

MediMap – pharmacogenomic testing for adults and children …

MediMap is a one-time Pharmacogenomics (or “PGx”) test that may indicate how a person will respond to specific prescription medications. Your MediMap test results can help guide your healthcare providers to ensure better medication choices and doses based on your genetic makeup… leading to more effective illness management and improved health Continue reading

Posted in Pharmacogenomics | Comments Off on MediMap – pharmacogenomic testing for adults and children …

Updating the landscape of direct-to-consumer pharmacogenomic testing – Dove Medical Press

Back to Browse Journals Pharmacogenomics and Personalized Medicine Volume 10 Kelly K Filipski,John D Murphy,Kathy J Helzlsouer Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA Abstract: Pharmacogenomics has identified important druggene interactions that affect the safety and efficacy of medications. Continue reading

Posted in Pharmacogenomics | Comments Off on Updating the landscape of direct-to-consumer pharmacogenomic testing – Dove Medical Press

Home [www.esptnet.eu]

(April 14, 2017) Dear ESPT member,First of all, I would like to thank you for your continued support of the European Society for Pharmacogenomics and Personalized Therapy (ESPT). With this email, I would like to update you on the activities of ESPT, and inform you about interactions with you as members regarding the direction and strategies of our society. The ESPT Board has been strengthened in October 2016 by Dr .Sanja Stankovic (Belgrade, Serbia) and Csilla Sipeky (Turku, Finland) Continue reading

Posted in Pharmacogenomics | Comments Off on Home [www.esptnet.eu]